ArticleAnnals of surgical oncology2025
Additional Axillary Disease After Neoadjuvant Chemotherapy for Patients with Clinically Node-Negative but Sentinel Node-Positive Disease.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAxillary lymph node dissection (ALND) is associated with considerable risk of arm morbidity. This study aimed to identify risk factors for additional disease found at ALND in patients with a diagnosis of clinically node-negative (cN0) breast cancer who had sentinel lymph node (SLN) metastasis after neoadjuvant chemotherapy (NACT) as a help to identify patients for whom ALND may be safely omitted.
methodsThis retrospective national cohort study analyzed Danish patients with a diagnosis of cT1-3 breast cancer and cN0 disease from October 2016 to November 2022 but a positive SLN biopsy after NACT. Uni- and multivariable logistic regression analyses with stepwise backward elimination were performed to identify factors predictive of additional axillary disease at ALND.
resultsThe study identified 346 patients eligible for analyses. Additional disease at ALND was found in 111 patients (32 %), but only 11 % of those with isolated tumor cells in the SLNs had additional axillary disease. It was respectively 22 % and 42 % for micro- and macrometastases. The final multivariable model identified the size of the metastatic deposit in the SLN, the ratio of positive SLNs, extracapsular extension, multifocality, and clinical T-stage as significant predictors of additional axillary disease.
conclusionPatients with isolated tumor cells in the sentinel nodes after NACT have a limited risk of additional axillary disease at ALND. However, other factors influence the probability and may be considered in an individualized approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.